project id: TCGA-BLCA; case submitter id: TCGA-FD-A5BY; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.87; concentration: 0.15; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.39; rna integrity number: 8.2; age at index: 63; days to birth: -23080; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Alive; year of birth: 1949; age at diagnosis: 23080; ajcc pathologic m: MX; ajcc pathologic n: N0; ajcc pathologic stage: Stage III; ajcc pathologic t: T3a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 251.0; icd 10 code: C67.4; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Posterior wall of bladder; synchronous malignancy: Not Reported; tissue or organ of origin: Posterior wall of bladder; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 90; days to sample procurement: 0; initial weight: 540.0; portion submitter id: TCGA-FD-A5BY-01A-31; percent lymphocyte infiltration: 6.0; percent monocyte infiltration: 2.0; percent necrosis: 6.0; percent neutrophil infiltration: 3.0; percent normal cells: 0.0; percent stromal cells: 34.0; percent tumor cells: 60.0; percent tumor nuclei: 80.0;